Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune
responses of the body. It has become another important modality of anti-tumor therapy with …

Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over
the past five decades with now over 90% of children achieving long-term survival. A direct …

Importance Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with
efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) …

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …

Background: A comprehensive approach to the evaluation of biologic therapies for
musculoskeletal conditions is required to guide appropriate future use. Clinical studies …

Acute kidney injury due to high‐dose methotrexate (HDMTX) is a serious, life‐threatening
toxicity that can occur in pediatric and adult patients. Glucarpidase is a treatment approved …

Improvements in risk-directed treatment and supportive care, together with increased
reliance on both national and international collaborative studies, have made childhood …

Truncation of asparaginase treatment due to asparaginase-related toxicities or silent
inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia …

PURPOSE In the DCOG ALL-11 protocol, polyethylene glycol–conjugated Escherichia coli
asparaginase (PEGasparaginase) and Erwinia asparaginase treatment of pediatric acute …

The aim of treating childhood cancer remains to cure all. As survival rates improve, long-
term health outcomes increasingly define quality of care. The International Childhood …